Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.880
-0.060 (-3.09%)
Oct 8, 2026, 11:48 AM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $342.3 million as of October 8, 2026. It is the 17,320th most valuable company in the world and the 3,048th biggest in the United States. Its market cap has increased by 134.69% in one year.
Market Cap
342.30M
Enterprise Value
183.28M
1-Year Change
134.69%
Global Rank
Country Rank
#3,048 United States
Category
ChartMarket Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $342.30M, an increase of 240.74%. That is a compound annual growth rate of 23.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 8, 2026 | 342.30M | 22.07% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Galectin Therapeutics | 373.65M |
| Turn Therapeutics | 373.54M |
| Fennec Pharmaceuticals | 367.85M |
| Enanta Pharmaceuticals | 365.52M |
| Arcturus Therapeutics Holdings | 364.38M |
| C4 Therapeutics | 351.24M |
| Artiva Biotherapeutics | 351.03M |
| Relmada Therapeutics | 349.34M |